title: Nano-carrier mediated co-delivery of methyl prednisolone and minocycline for improved post-traumatic spinal cord injury conditions in rats.
abstract: OBJECTIVE
  The objective of this study is to investigate the fate of albumin coupled nanoparticulate system over non-targeted drug carrier in the treatment of hemisectioned spinal cord injury (SCI).
  
  
  CONCLUSIONS
  Targeted delivery of methyl prednisolone (MP) and minocycline (MC) portrayed improved therapeutic efficacy as compared with non-targeted nanoparticles (NPS).
  
  
  METHODS
  Albumin coupled, chitosan stabilized, and cationic NPS (albumin-MP + MC - NPS) of poly-(lactide-co-glycolic acid) were prepared using the emulsion solvent evaporation method. Prepared NPS were characterized for drug entrapment efficiency, particle size, poly-dispersity index (PDI), zeta potential, and morphological characteristics. Their evaluation was done based on the pharmaceutical, toxicological, and pharmacological parameters.
  
  
  CONCLUSIONS
  In vitro release of MP + MC from albumin-MP + MC - NPS and MP + MC - NPS was observed to be very controlled for the period of eight days. Cell viability study portrayed non-toxic nature of the developed NPS. Albumin-MP + MC - NPS showed prominent anti-inflammatory potential as compared with non-targeted NPS (MP + MC - NPS) when studied in LPS-induced inflamed astrocytes. Albumin-MP + MC - NPS reduced lesional volume and improved behavioral outcomes significantly in rats with SCI (hemisectioned injury model) when compared with that of MP + MC - NPS.
  
  
  CONCLUSIONS
  Albumin-coupled NPS carrier offered an effective method of SCI treatment following safe co-administration of MP and MC. The in vitro and in vivo effectiveness of MP + MC was improved tremendously when compared with the effectiveness showed by MP + MC - NPS. That could be attributed to the site specific, controlled release of MP + MC to the inflammatory site.
authors.affiliation: a Department of Spine Surgery , Shanghai East Hospital , Shanghai , China.
authors.forename: Shen
authors.initials: S
authors.lastname: Bin
authors.affiliation: a Department of Spine Surgery , Shanghai East Hospital , Shanghai , China.
authors.forename: Ningfeng
authors.initials: N
authors.lastname: Zhou
authors.affiliation: a Department of Spine Surgery , Shanghai East Hospital , Shanghai , China.
authors.forename: Jie
authors.initials: J
authors.lastname: Pan
authors.affiliation: a Department of Spine Surgery , Shanghai East Hospital , Shanghai , China.
authors.forename: Fumin
authors.initials: F
authors.lastname: Pan
authors.affiliation: b Department of Orthopaedics , Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine , Shanghai , China.
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Wu
authors.affiliation: a Department of Spine Surgery , Shanghai East Hospital , Shanghai , China.
authors.forename: Zi-Hui
authors.initials: ZH
authors.lastname: Zhou
mesh_terms: D000418:Albumins / Q000737:chemistry; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001253:Astrocytes / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D048271:Chitosan / Q000737:chemistry; D004337:Drug Carriers; D004338:Drug Combinations; D016503:Drug Delivery Systems; D005260:Female; D019344:Lactic Acid; D008775:Methylprednisolone / Q000627:therapeutic use*; D008911:Minocycline / Q000627:therapeutic use*; D053758:Nanoparticles; D010316:Particle Size; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D017207:Rats, Sprague-Dawley; D013119:Spinal Cord Injuries / Q000188:drug therapy*
chemical_list: D000418:Albumins; D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D004338:Drug Combinations; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D048271:Chitosan; D008911:Minocycline; D008775:Methylprednisolone
keywords: PLGA; Spinal cord injury; albumin-coupled nanoparticle; methyl prednisolone; minocycline